CD26 upregulates proliferation and invasion in keloid fibroblasts through an IGF-1-induced PI3K/AKT/mTOR pathway

Abstract

Background: Keloid is a fibrotic dermal disease characterized by an abnormal increase in fibroblast proliferation and invasion. These pathological behaviours may be related to the heterogeneity of keloid fibroblasts (KFs); however, because of a lack of effective biomarkers for KFs it is difficult to study the underlying mechanism. Our previous studies revealed that the expansion of CD26+ KFs was responsible for increased keloid proliferation and invasion capabilities; the intrinsic relationship and mechanism between CD26 and keloid is therefore worthy of further investigation. The aim of this study was to explore molecular mechanisms in the process of CD26 upregulated KFs proliferation and invasion abilities, and provide more evidence for CD26 as an effective biomarker of keloid and a new clinical therapeutic target. Methods: Flow cytometry was performed to isolate CD26+/CD26− fibroblasts from KFs and normal fibroblasts. To generate stably silenced KFs for CD26 and insulin-like growth factor-1 receptor (IGF-1R), lentiviral particles encoding shRNA targeting CD26 and IGF-1R were used for transfection. Cell proliferations were analysed by cell counting kit-8 assay and 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay. Scratching assay and transwell assay were used to assess cell migration and invasion abilities. To further quantify the regulatory role of CD26 expression in the relevant signalling pathway, RT-qPCR, western blot, ELISA, PI3K activity assay and immunofluorescence were used. Results: Aberrant expression of CD26 in KFs was proven to be associated with increased proliferation and invasion of KFs. Furthermore, the role of the IGF-1/IGF-1 receptor axis was also studied in CD26 and was found to upregulate KF proliferation and invasion. The PI3K/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway was shown to affect CD26-regulated KF proliferation and invasion by increasing phosphorylation levels of S6 kinase and 4E-binding protein. Conclusions: CD26 can be the effective biomarker for KFs, and its expression is closely related to proliferation and invasion in keloids through the IGF-1-induced PI3K/AKT/mTOR pathway. This work provides a novel perspective on the pathological mechanisms affecting KFs and therapeutic strategies against keloids.

Keywords

CD26 / IGF-1 / Invasion / Keloids / PI3K/AKT/mTOR signalling pathway / Proliferation / Fibroblast

References

[1] Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999; 104: 1435-58.

[2] Vincent AS, Phan TT, Mukhopadhyay A, Lim HY, Halliwell B, Wong KP. Human skin keloid fibroblasts display bioenergetics of cancer cells. J Invest Dermatol. 2008; 128: 702-9.

[3] Wang W, Qu M, Xu L, Wu X, Gao Z, Gu T, et al. Sorafenib exerts an anti-keloid activity by antagonizing TGF-beta/Smad and MAPK/ERK signaling pathways. J Mol Med (Berl) 2016; 94: 1181- 94.

[4] Shih B, Garside E, McGrouther DA, Bayat A. Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Repair Regen. 2010; 18: 139-53.

[5] Zhang Z, Nie F, Kang C, Chen B, Qin Z, Ma J, et al. Increased periostin expression affects the proliferation, collagen synthesis, migration and invasion of keloid fibroblasts under hypoxic conditions. Int J Mol Med. 2014; 34: 253-61.

[6] Srivastava S, Kumari H, Singh A. Comparison of fractional CO2 laser, verapamil, and triamcinolone for the treatment of keloid. Adv Wound Care (New Rochelle). 2019; 8: 7-13.

[7] Feng JJ, See JL, Choke A, Ooi A, Chong SJ. Biobrane^TM for burns of the pubic region: minimizing dressing changes. Military Med Res. 2018; 5: 29.

[8] Lee YS, Hsu T, Chiu WC, Sarkozy H, Kulber DA, Choi A, et al. Keloid-derived, plasma/fibrin-based skin equivalents generate de novo dermal and epidermal pathology of keloid fibrosis in a mouse model. Wound Repair Regen. 2016; 24: 302-16.

[9] Ghazizadeh M, Tosa M, Shimizu H, Hyakusoku H, Kawanami O. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol. 2007; 127: 98-105.

[10] Yu C, Xu ZX, Hao YH, Gao YB, Yao BW, Zhang J, et al. A novel microcurrent dressing for wound healing in a rat skin defect model. Mil Med Res. 2019; 6(1): 22.

[11] Ashcroft KJ, Syed F, Bayat A. Site-specific keloid fibroblasts alter the behaviour of normal skin and normal scar fibroblasts through paracrine signalling. Site-specific keloid fibroblasts alter the behaviour of normal skin and normal scar fibroblasts through paracrine signalling. PLoS One. 2013; 8(12): e75600. doi: 10.1371/journal.pone.0075600

[12] Rinkevich Y, Walmsley GG, Hu MS, Maan ZN, Newman AM, Drukker M, et al. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science. 2015; 348: aaa2151.

[13] Mah W, Jiang G, Olver D, Gallant-Behm C, Wiebe C, Hart DA, et al. Elevated CD26 expression by skin fibroblasts distinguishes a Profibrotic phenotype involved in scar formation compared to gingival fibroblasts. Am J Pathol. 2017; 187: 1717-35.

[14] Leavitt T, Hu MS, Marshall CD, Barnes LA, Lorenz HP, Longaker LMT. Scarless wound healing: finding the right cells and signals. Cell Tissue Res. 2016; 365: 483-93.

[15] Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of Dipeptidyl Peptidase-4 inhibitors. Endocr Rev. 2014; 35: 992-1019.

[16] Ohnuma K, Nam HD, Chikao M. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008; 29: 295-301.

[17] Krakauer. M, Sorensen PS, Sellebjerg F. CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol. 2006; 181: 157-64.

[18] K E, Y U, C S, T O, H N, K M, et al. Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves’ disease. J Immunol. 1989; 142.

[19] Alina S, Hermina AG, Alexandru EM, Clara D, Simon R, Thomas W, et al. Dipeptidyl-peptidase-4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in Systemic Sclerosis. Hoboken, N.J.: Arthritis & rheumatology, 2020; 72: 137-149.

[20] Alina S, Hermina AG, Alexandru EM, Clara D, Simon R, Thomas W, et al. Dipeptidyl-peptidase-4 as amarker of activated fibroblasts and a potential target for the treatment of fibrosis in Systemic Sclerosis. Hoboken, N.J.: Arthritis & rheumatology, 2020; 72: 137-149.

[21] Györfi AH, Matei A-E, Distler JHW. Targeting TGF-β signaling for the treatment of fibrosis. Matrix Biol. 2018; 8: 68-9.

[22] Hong S-K, Choo E-H, Ihm S-H, Chang K, Seung K-B. Dipeptidyl peptidase 4 inhibitor attenuates obesity-induced myocardial fibrosis by inhibiting transforming growth factor-βl and Smad 2/3 pathways in high-fat diet-induced obesity rat model. Metabolism. 2017; 76: 42-55.

[23] Chen J, Alberts I, Li X. Dysregulation of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders. Int J Dev Neurosci. 2014; 35: 35-41.

[24] Shih B, Bayat A. Genetics of keloid scarring. Genetics of keloid scarring. Arch Dermatol Res. 2010; 302: 319-39.

[25] Ishihara H, Yoshimoto H, Fujioka M, Murakami R, Hirano A, Fujii T, et al. Keloid fibroblasts resist ceramide-induced apoptosis by overexpression of insulin-like growth factor I receptor. J Invest Dermatol. 2000; 115: 1065-71.

[26] Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. Curr Pharm Des. 2007; 13: 663-9.

[27] Yoshimoto H, Ishihara H, Ohtsuru A, Akino K, Murakami R, Kuroda H, et al. Overexpression of insulin-like growth factor-1 (IGF-I) receptor and the invasiveness of cultured keloid fibroblasts. Am J Pathol. 1999; 154: 883-9.

[28] Xue G, Hemmings BA. PKB/Akt-dependent regulation of cell motility. PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst. 2013; 105: 393-404.

[29] Syed F, Sherris D, Paus R, Varmeh S, Singh S, Pandolfi PP, et al. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor. Am J Pathol. 2012; 181: 1642-58.

[30] Beugnet A, Wang X, Proud CG. Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1. J Biol Chem. 2003; 278: 40717-22.

[31] Lu F, Gao J, Ogawa R, Hyakusoku H, Ou C. Biological differences between fibroblasts derived from peripheral and central areas of keloid tissues. Plast Reconstr Surg. 2007; 120: 625-30.

[32] Song J, Xu H, Lu Q, Xu Z, Bian D, Xia Y, et al. Madecassoside suppresses migration of fibroblasts from keloids: involvement of p38 kinase and PI3K signaling pathways. Burns. 2012; 38: 677-84.

[33] Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015; 15: 7-24.

[34] Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9: 550-62.

[35] Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010; 28: 1075-83.

[36] Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 2011; 3: 192-222.

[37] Wegiel B, Bjartell A, Culig Z, Persson JL. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer. 2008; 122: 1521-9.

[38] Luo S, Benathan M, Raffoul W, Panizzon RG, Egloff DV. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast Reconstr Surg. 2001; 107: 87-96.

[39] Jung FJ, Yang L, De Meester I, Augustyns K, Cardell M, Hillinger S, et al. CD26/dipeptidylpeptidase IV-targeted therapy of acute lung rejection in rats. J Heart Lung Transplant. 2006; 25: 1109-16.

[40] Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007; 21: 517-33.

[41] Ocana A, Amir E, Seruga B, Martin M, Pandiella A. The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treat Rev. 2013; 39: 68-76.

[42] Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008; 27: 5511-26.